Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Financial Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 321,992 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Exercise / conversion · Acquired 61,378 · Balance 321,992 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F2: This number includes 373 shares acquired under the Registrant's employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 320,492 |
Reported balance
After 2026-06-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-30 · Sale · Disposed 1,500 · Balance 320,492 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 318,792 |
Reported balance
After 2026-06-30 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-06-30 · Sale · Disposed 1,700 · Balance 318,792 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 317,692 |
Reported balance
After 2026-06-30 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-06-30 · Sale · Disposed 1,100 · Balance 317,692 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 313,582 |
Reported balance
After 2026-06-30 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-06-30 · Sale · Disposed 4,110 · Balance 313,582 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 262,207 |
Reported balance
After 2026-06-30 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-06-30 · Sale · Disposed 51,375 · Balance 262,207 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 254,236 |
Reported balance
After 2026-06-30 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2026-06-30 · Sale · Disposed 7,971 · Balance 254,236 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 248,083 |
Reported balance
After 2026-06-30 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2026-06-30 · Sale · Disposed 6,153 · Balance 248,083 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 244,883 |
Reported balance
After 2026-06-30 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2026-06-30 · Sale · Disposed 3,200 · Balance 244,883 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2030-05-13 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-30 · Exercise / conversion · Disposed 61,378 · Balance 0 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F11: The shares underlying this stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person.
F2: This number includes 373 shares acquired under the Registrant's employee stock purchase plan.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11: The shares underlying this stock option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2022 Filed Oct 18, 2022 00:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-033710 · doc4.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 00:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-22-033710 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 465 shares acquired under the Registrant's employee stock purchase plan on May 31, 2022. Read SEC document |
| May 03, 2022 Filed May 3, 2022 23:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-016429 · doc4.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,899 Underlying: Common Stock · 20,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| May 03, 2022 Filed May 3, 2022 23:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 20,000 | $2.08 | $41,600.00 |
DisclosureSEC source: 0000899243-22-016429 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $38.53 | $0.00 |
DisclosureSEC source: 0000899243-22-009078 · doc4.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-29 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009078 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,814 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 14, 2022 Filed Jan 14, 2022 22:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-002016 · doc4.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 14, 2022 Filed Jan 14, 2022 22:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-22-002016 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-002010 · doc4.xml · derivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,974 Underlying: Common Stock · 15,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,422 | $53.27 | $75,746.81 |
DisclosureSEC source: 0000899243-22-002010 · doc4.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,514 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.01 to $53.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,151 | $52.13 | $372,788.07 |
DisclosureSEC source: 0000899243-22-002010 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,936 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.71 to $52.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,427 | $51.21 | $329,149.16 |
DisclosureSEC source: 0000899243-22-002010 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,087 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.70 to $51.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0000899243-22-002010 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2021 Filed Dec 3, 2021 23:43 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-046845 · doc4.xml · derivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| December 03, 2021 Filed Dec 3, 2021 23:43 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 300 | $55.07 | $16,520.01 |
DisclosureSEC source: 0000899243-21-046845 · doc4.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,514 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.96 to $55.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 03, 2021 Filed Dec 3, 2021 23:43 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,987 | $54.32 | $107,929.27 |
DisclosureSEC source: 0000899243-21-046845 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,814 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.92 to $54.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 03, 2021 Filed Dec 3, 2021 23:43 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,713 | $53.31 | $411,187.74 |
DisclosureSEC source: 0000899243-21-046845 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,801 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.91 to $53.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 03, 2021 Filed Dec 3, 2021 23:43 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-21-046845 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 258 shares acquired under the Registrant's employee stock purchase plan on November 30, 2021. Read SEC document |
| November 23, 2021 Filed Nov 23, 2021 21:59 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-045803 · doc4.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 23, 2021 Filed Nov 23, 2021 21:59 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-21-045803 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 21:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-035158 · doc4.xml · derivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 21:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,500 | $60.50 | $90,744.00 |
DisclosureSEC source: 0000899243-21-035158 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,256 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.42 to $60.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 21:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,500 | $60.05 | $510,436.05 |
DisclosureSEC source: 0000899243-21-035158 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,756 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.41 to $60.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 21:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-21-035158 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-022025 · doc4.xml · derivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,494 | $47.13 | $211,790.09 |
DisclosureSEC source: 0000899243-21-022025 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,256 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.93 to $47.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,506 | $46.66 | $256,905.00 |
DisclosureSEC source: 0000899243-21-022025 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,494 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.93 to $46.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-21-022025 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 256 shares acquired under the Registrant's employee stock purchase plan for the period ended May 31, 2021. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 22:37 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-015650 · doc4.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,899 Underlying: Common Stock · 7,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 22:37 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 7,000 | $2.08 | $14,560.00 |
DisclosureSEC source: 0000899243-21-015650 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 01:08 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,195 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-011747 · doc4.xml · derivative · entry 6 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,061 Underlying: Common Stock · 8,195 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 01:08 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,195 | $60.17 | $493,095.61 |
DisclosureSEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.675. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 01:08 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 8,195 | $2.08 | $17,045.60 |
DisclosureSEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 16, 2021 01:08 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,805 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-011747 · doc4.xml · derivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,256 Underlying: Common Stock · 1,805 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date Read SEC document |
| March 11, 2021 Filed Mar 16, 2021 01:08 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,805 | $60.07 | $108,431.95 |
DisclosureSEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 11, 2021 Filed Mar 16, 2021 01:08 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 1,805 | $2.08 | $3,754.40 |
DisclosureSEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-010463 · doc4.xml · derivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,061 Underlying: Common Stock · 10,000 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1 | $52.15 | $52.15 |
DisclosureSEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,300 | $51.28 | $117,936.41 |
DisclosureSEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,699 | $50.46 | $388,481.53 |
DisclosureSEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,301 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-010156 · doc4.xml · derivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,061 Underlying: Common Stock · 20,000 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,100 | $45.75 | $50,322.80 |
DisclosureSEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.60 to $46.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 12,019 | $45.07 | $541,699.94 |
DisclosureSEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.60 to $45.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,881 | $44.12 | $303,611.05 |
DisclosureSEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,119 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.56 to $44.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 20,000 | $2.08 | $41,600.00 |
DisclosureSEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:27 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $48.46 | $0.00 |
DisclosureSEC source: 0000899243-21-009388 · doc4.xml · derivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 22:21 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 32,904 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023227 · doc4.xml · derivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,904 Underlying: Common Stock · 32,904 shares Expires 2030-08-19 F1 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments over four (4) years commencing on the date of the Registration Statement Effectiveness. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.